Enhancing comparative rabies DNA vaccine effectiveness through glycoprotein gene modifications (Q43238589)

17 November 2017

Enhancing comparative rabies DNA vaccine effectiveness through glycoprotein gene modifications (English)

1 reference

17 November 2017

0 references

M O V Osinubi

1

1 reference

17 November 2017

X Wu

2

1 reference

17 November 2017

R Franka

3

1 reference

17 November 2017

M Niezgoda

4

1 reference

17 November 2017

A J Nok

5

1 reference

17 November 2017

A B Ogunkoya

6

1 reference

17 November 2017

C E Rupprecht

7

1 reference

17 November 2017

language of work or name

English

0 references

publication date

1 November 2009

1 reference

17 November 2017

5

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

17 November 2017

27

1 reference

17 November 2017

51

1 reference

17 November 2017

7214-7218

1 reference

Hospital records of human rabies and antirabies prophylaxis in Nigeria 1969–1978

17 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.031

Vaccination challenge studies with variants of street rabies virus isolated in Nigeria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.031

Field trials of a very potent rabies DNA vaccine which induced long lasting virus neutralizing antibodies and protection in dogs in experimental conditions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.031

Memory and cellular immunity induced by a DNA vaccine encoding self antigen TPD52 administered with soluble GM-CSF.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.031

Coimmunization with an optimized IL15 plasmid adjuvant enhances humoral immunity via stimulating B cells induced by genetically engineered DNA vaccines expressing consensus JEV and WNV E DIII.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.031

Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.031

Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.031

Nanogram quantities of plasmid DNA encoding the rabies virus glycoprotein protect mice against lethal rabies virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.031

DNA immunization protects nonhuman primates against rabies virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.031

Immunization of dogs with a DNA vaccine induces protection against rabies virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.031

Post-exposure DNA vaccination protects mice against rabies virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.031

Rabies DNA vaccination of non-human primates: post-exposure studies using gene gun methodology that accelerates induction of neutralizing antibody and enhances neutralizing antibody titers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.031

Canine rabies DNA vaccination: a single-dose intradermal injection into ear pinnae elicits elevated and persistent levels of neutralizing antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.031

Rabies DNA vaccine in the horse: strategies to improve serological responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.031

Impact of plasmid supercoiling on the efficacy of a rabies DNA vaccine to protect cats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.031

Intradermal DNA vaccination in ear pinnae is an efficient route to protect cats against rabies virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.031

A sindbis virus replicon-based DNA vaccine encoding the rabies virus glycoprotein elicits immune responses and complete protection in mice from lethal challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.031

Efficient post-exposure prophylaxis against rabies by applying a four-dose DNA vaccine intranasally.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.031

Characterization of an antigenic determinant of the glycoprotein that correlates with pathogenicity of rabies virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.031

Genetic engineering of live rabies vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.031

Arginine or lysine in position 333 of ERA and CVS glycoprotein is necessary for rabies virulence in adult mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.031

Immunization of dogs and cats with a DNA vaccine against rabies virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.031

Glycoprotein gene relocation in rabies virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.031

Both viral transcription and replication are reduced when the rabies virus nucleoprotein is not phosphorylated

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.031

Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.031

Protective immunity by intramuscular injection of low doses of influenza virus DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.031

Immune responses to nucleic acid vaccines to rabies virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.031

DNA-based immunization for exploring the enlargement of immunological cross-reactivity against the lyssaviruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.031

One-time intradermal DNA vaccination in ear pinnae one year prior to infection protects dogs against rabies virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.031

Generation of potent and specific cellular immune responses via in vivo stimulation of dendritic cells by pNGVL3-hFLex plasmid DNA and immunogenic peptides.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.031

Immunopotentiation of the antibody response against influenza HA with apoptotic bodies generated by rabies virus G-ERA protein-driven apoptosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.031

Glycoprotein-mediated induction of apoptosis limits the spread of attenuated rabies viruses in the central nervous system of mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.031

Comparative pathogenesis of recombinant rabies vaccine strain SAD-L16 and SAD-D29 with replacement of Arg333 in the glycoprotein after peripheral inoculation of neonatal mice: less neurovirulent strain is a stronger inducer of neuronal apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.031

Rabies virus infects mouse and human lymphocytes and induces apoptosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.031

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2009.09.031

1 reference

17 November 2017

1 reference